‘Landmark’: New mRNA vaccine could prevent skin cancer from returning, companies say

Moderna and Merck said the personalised vaccine reduced the risk of recurrence and spread of melanoma in a late-stage trial, a major success in a new field of cancer treatment.

Moderna and Merck said the personalised vaccine reduced the risk of recurrence and spread of melanoma in a late-stage trial, a major success in a new field of cancer treatment.

The combined drug works by nudging the body's own immune system to make proteins that attack and destroy melanoma cells

Pharmaceutical companies Moderna and Merck announced today the highly promising results of their anti-cancer mRNA vaccine Phase 3 clinical trial targeting later-stage melanoma skin cancers. Researchers sequenced the DNA from each patient's tumors to create personalized vaccines that, when injected, rev up the immune sy

A new personalised vaccine could halve the risk of skin cancer returning in high-risk patients, a large trial has found.

The shot, paired with Merck's Keytruda, cut the risk of melanoma recurrence in a trial of more than 1,100 patients.

The results mark a step forward in the effort to treat not just melanoma but other forms of cancer with vaccines designed to help keep patients disease-free.

Promising new cancer treatment is based on sequencing a tumour's DNA and making a patient's immune system attack their cancer cells

Moderna and Merck say the experimental vaccine prevented the return and spread of the cancer in high-risk melanoma patients.

An experimental personalized mRNA-based cancer vaccine from Merck and Moderna was successful at preventing melanoma from returning or spreading in a late-stage trial of high risk patients, the companies announced Wednesday.   The positive results mean a potentially life-extending treatment is one step closer to being a

The candidate is a combination of an mRNA therapeutic vaccine and Merck’s cancer drug Keytruda.

More than 8,500 Americans are expected to die of melanoma this year

Landmark vaccine stops cancer returning in trial  The Times